ARS Pharmaceuticals, Inc. Earnings Per Share, Basic and Diluted
ARS Pharmaceuticals, Inc. (SPRY) reported Earnings Per Share, Basic and Diluted of -$0.55 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-08-11
- ARS Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2022-06-30 was -$0.55.
- ARS Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.70.
- ARS Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was $1.31.
- ARS Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.65.
- ARS Pharmaceuticals, Inc. earnings per share, basic and diluted for fiscal 2021 was -$2.56.
- ARS Pharmaceuticals, Inc. earnings per share, basic and diluted for fiscal 2020 was -$11.33.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$0.55 10-Q · filed 2022-08-11 | -$1.25 10-Q · filed 2022-08-11 | $0.91 derived: net income ÷ weighted average shares · filed 2023-08-10 | $0.27 derived: net income ÷ weighted average shares · filed 2023-08-10 |
| 2022-03-31 | -$0.70 10-Q · filed 2022-05-12 | $1.10 derived: net income ÷ weighted average shares · filed 2023-05-15 | $0.45 derived: net income ÷ weighted average shares · filed 2023-05-15 | -$0.25 derived: net income ÷ weighted average shares · filed 2023-05-15 |
| 2021-12-31 | $1.31 derived: net income ÷ weighted average shares · filed 2023-03-23 | $0.66 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$0.04 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$2.56 10-K · filed 2022-03-31 |
| 2021-09-30 | -$0.65 10-Q · filed 2021-11-10 | -$1.35 derived: net income ÷ weighted average shares · filed 2022-11-02 | -$1.89 10-Q · filed 2021-11-10 | -$2.77 derived: net income ÷ weighted average shares · filed 2022-11-02 |
| 2021-06-30 | -$0.70 10-Q · filed 2022-08-11 | -$1.25 10-Q · filed 2022-08-11 | -$2.14 derived: net income ÷ weighted average shares · filed 2022-08-11 | -$3.23 derived: net income ÷ weighted average shares · filed 2022-08-11 |
| 2021-03-31 | -$0.54 10-Q · filed 2022-05-12 | -$1.44 derived: net income ÷ weighted average shares · filed 2022-08-11 | -$2.67 derived: net income ÷ weighted average shares · filed 2022-08-11 | -$4.07 derived: net income ÷ weighted average shares · filed 2022-08-11 |
| 2020-12-31 | -$1.36 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$4.12 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$7.57 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$11.33 10-K · filed 2022-03-31 |
| 2020-09-30 | -$11.97 10-Q · filed 2021-11-10 | -$21.63 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$29.53 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$9.65 10-Q · filed 2021-08-12 | -$17.54 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$7.89 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |